Takeda Pharmaceutical (TAK) Income from Non-Controlling Interests (2017 - 2026)

Takeda Pharmaceutical has reported Income from Non-Controlling Interests for 10 years, with the latest figure at $376434.2 in Q2 2026.

• On a quarterly basis, Income from Non-Controlling Interests rose 51.3% year-over-year to $376434.2 in Q2 2026; TTM through Jun 2026 was -$2.3 million, a 5.69% increase from a year earlier, with the FY2026 full-year figure at $1.7 million, up 19.27% from the prior year.
• Income from Non-Controlling Interests was $376434.2 for Q2 2026 at Takeda Pharmaceutical, up from -$637655.0 in the prior quarter.
• The five-year high for Income from Non-Controlling Interests was $376434.2 in Q2 2026, with the low at -$1.4 million in Q3 2025.
• Average Income from Non-Controlling Interests over 5 years is -$352612.9, with a median of -$391968.8 recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Income from Non-Controlling Interests sank 856.34% in 2023, then soared 308.17% in 2024.
• Over 5 years, Income from Non-Controlling Interests stood at $155723.0 in 2022, then sank by 544.66% to -$692442.5 in 2023, then advanced by 5.01% to -$657777.5 in 2024, then advanced by 1.21% to -$649790.1 in 2025, then jumped by 157.93% to $376434.2 in 2026.
• The last three Income from Non-Controlling Interests figures came in at $376434.2 (Q2 2026), -$637655.0 (Q1 2026), and -$649790.1 (Q4 2025), per Business Quant data.